Wird geladen...
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
PURPOSE: Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but most patients will experience primary or secondary treatment failure. The outcome of these patients has not yet been descr...
Gespeichert in:
| Veröffentlicht in: | J Clin Oncol |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society of Clinical Oncology
2011
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4859209/ https://ncbi.nlm.nih.gov/pubmed/21788559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.8135 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|